NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free ENGN Stock Alerts $15.50 +0.78 (+5.30%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$14.00▼$15.5050-Day Range$14.17▼$18.2452-Week Range$6.69▼$43.00Volume113,417 shsAverage Volume36,859 shsMarket Capitalization$675.49 millionP/E RatioN/ADividend YieldN/APrice Target$34.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get enGene alerts: Email Address enGene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.9% Upside$34.40 Price TargetShort InterestHealthy0.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 43 Articles This WeekInsider TradingSelling Shares$786,481 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector147th out of 913 stocksHolding & Other Investment Offices Industry1st out of 12 stocks 4.5 Analyst's Opinion Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.97% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in enGene has recently increased by 472.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENGN. Previous Next 1.8 News and Social Media Coverage News SentimentenGene has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for enGene this week, compared to 25 articles on an average week.MarketBeat FollowsOnly 2 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, enGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $786,481.00 in company stock.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About enGene Stock (NASDAQ:ENGN)enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More ENGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENGN Stock News HeadlinesApril 23, 2024 | insidertrades.comenGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder De Solidarite Des Travai Fonds Sells 4,575 SharesApril 23, 2024 | insidertrades.comDe Solidarite Des Travai Fonds Sells 47,854 Shares of enGene Holdings Inc. (NASDAQ:ENGN) StockApril 27, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 27, 2024 | news.yahoo.comBentley’s New Mulliner Will Have Its Most Powerful W-12 Engine EverApril 26, 2024 | msn.comHow to create realistic game interiors in Unreal Engine 5April 26, 2024 | yahoo.comBentley’s New Coachbuilt Model Will Have Its Most Powerful W-12 Engine EverApril 26, 2024 | msn.comEVs are adding fake engine noisesApril 26, 2024 | msn.comHow Much HP Does A C6 Corvette With A LS7 Engine Have & Why Were They Discontinued?April 27, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 25, 2024 | msn.comMopar 340 Vs. 360: Which Is The Better Engine?April 25, 2024 | msn.com10 Factors That Influence an Engine’s CharacterApril 25, 2024 | americanbankingnews.comenGene Holdings Inc. (NASDAQ:ENGN) Receives $34.40 Average Price Target from BrokeragesApril 24, 2024 | msn.comWhat Engine Is In The Dodge Scat Pack & Just How Fast It Can BeApril 24, 2024 | msn.comMopar 440 Vs 440 Magnum Engines: What's The Difference?April 24, 2024 | yahoo.com‘Keep him in your prayers’: Hillcrest fire chief suffers head injury after fall from fire engine, officials sayApril 24, 2024 | msn.comUnreal Engine 5.4 is here, and it's good news for filmmakers and animatorsApril 24, 2024 | yahoo.comThis BMW E36 Broke Its Engine—Then It Became a Dream CarApril 24, 2024 | msn.com5 Of The Most Reliable Engines Ever Made By PontiacApril 24, 2024 | msn.comFake engine noises in electric cars need to dieApril 24, 2024 | msn.comThe new 2025 Ford Explorer has a powerful engine, redesigned, upscale cabin and top safety ratingsApril 24, 2024 | msn.comTune Your Engine, Dial Your Suspension, Find Quicker Lines: KTM/Husqvarna ‘CUO’April 24, 2024 | seekingalpha.comMTU Aero Engines Can Fly Out Of Turbofan CrisisApril 23, 2024 | thetimes.co.ukAerospace driving Rolls-Royce’s profit engineApril 23, 2024 | msn.comUkraine seizes machine-building plant and Tu-95 aircraft engines owned by Russian Ministry of DefenceApril 23, 2024 | msn.comPerplexity brings its "answer engine" to enterprisesApril 23, 2024 | msn.comGM's LS1 Vs. LSX Engine: What's The Difference?April 23, 2024 | msn.comLargest UK fire engine aid convoy heads to UkraineSee More Headlines Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$34.40 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+121.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$30,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2.39% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.00 per share Price / Cash Flow7,590.96 Book Value($0.26) per share Price / Book-59.62Miscellaneous Outstanding Shares43,580,000Free FloatN/AMarket Cap$675.49 million OptionableN/A Beta-0.49 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Jason D. Hanson Esq. (Age 55)J.D., CEO & Director Comp: $656.58kDr. Alex Nichols Ph.D. (Age 38)President & COO Comp: $504.44kDr. James C. Sullivan M.Sc. (Age 45)Ph.D., Chief Scientific Officer Comp: $524.29kDr. Anthony T. Cheung Ph.D. (Age 52)Co-Founder & CTO Comp: $341.75kMr. John C. Brown D.Sc.FRSC, Ph.D., Co-Founder and Member of Scientific Advisory BoardMr. David Ryan Daws (Age 50)CFO & Head of Business Development Mr. Lee G. Giguere (Age 43)Chief Legal Officer & Corporate Secretary Ms. Sharon TanVP of Project Management & Head of Program ManagementDr. Richard P. Bryce MBChB (Age 67)MFPM, MRCGP, Chief Medical Officer Mr. Paul EricksonNon-Executive DirectorMore ExecutivesKey CompetitorsCogent BiosciencesNASDAQ:COGTTreace Medical ConceptsNASDAQ:TMCIY-mAbs TherapeuticsNASDAQ:YMABSilence TherapeuticsNASDAQ:SLNEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsDe Solidarite Des Travai FondsSold 47,854 sharesTotal: $717,810.00 ($15.00/share)De Solidarite Des Travai FondsSold 4,575 sharesTotal: $68,670.75 ($15.01/share)Fcpm Iii Services B.V.Bought 8,677,951 shares on 3/7/2024Ownership: 37.408%BVF Inc. ILBought 2,251,037 shares on 2/15/2024Ownership: 9.703%Omega Fund Management LLCBought 1,131,175 shares on 2/15/2024Ownership: 4.876%View All Insider TransactionsView All Institutional Transactions ENGN Stock Analysis - Frequently Asked Questions Should I buy or sell enGene stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for enGene in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENGN shares. View ENGN analyst ratings or view top-rated stocks. What is enGene's stock price target for 2024? 6 Wall Street analysts have issued 1-year price objectives for enGene's stock. Their ENGN share price targets range from $30.00 to $40.00. On average, they expect the company's share price to reach $34.40 in the next twelve months. This suggests a possible upside of 121.9% from the stock's current price. View analysts price targets for ENGN or view top-rated stocks among Wall Street analysts. How have ENGN shares performed in 2024? enGene's stock was trading at $9.23 at the beginning of the year. Since then, ENGN shares have increased by 67.9% and is now trading at $15.50. View the best growth stocks for 2024 here. Are investors shorting enGene? enGene saw a increase in short interest in April. As of April 15th, there was short interest totaling 72,700 shares, an increase of 472.4% from the March 31st total of 12,700 shares. Based on an average trading volume of 51,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 1.0% of the shares of the company are sold short. View enGene's Short Interest. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENGN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
